Under the terms of the agreement, Roche will provide Entelos with R&D funding and milestone payments for biosimulation research conducted using its Metabolism PhysioLab platform, the companies said.
Roche said that Entelos' approach could be "useful in analyzing existing preclinical and clinical data in order to optimize future clinical trials" for drugs or tests that treat chronic metabolic disorders like diabetes and obesity.
Financial terms were not disclosed.